Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381342 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Exenatide as Monotherapy
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
NCT00381342 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 233 participants.
The verdict
NCT00381342, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
Study Summary
This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.
Interventions
- DRUG placebo
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381342
The ClinicalTrials.gov registry entry for NCT00381342 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00381342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381342 about?
NCT00381342 is a clinical study titled "Safety and Efficacy of Exenatide as Monotherapy". This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.
What is the current status of trial NCT00381342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2006-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00381342?
The interventions under investigation include: placebo (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00381342?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.